1. Home
  2. KODK vs FULC Comparison

KODK vs FULC Comparison

Compare KODK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

HOLD

Current Price

$6.97

Market Cap

658.4M

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.65

Market Cap

718.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KODK
FULC
Founded
1880
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.4M
718.4M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
KODK
FULC
Price
$6.97
$7.65
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
559.1K
1.1M
Earning Date
06-23-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,114,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$2.32
52 Week High
$9.96
$15.74

Technical Indicators

Market Signals
Indicator
KODK
FULC
Relative Strength Index (RSI) 41.84 33.14
Support Level $6.94 $7.40
Resistance Level $7.09 $7.64
Average True Range (ATR) 0.31 0.65
MACD -0.02 -0.09
Stochastic Oscillator 28.52 6.49

Price Performance

Historical Comparison
KODK
FULC

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Share on Social Networks: